Genic Co. Ltd (123330) - Net Assets
Based on the latest financial reports, Genic Co. Ltd (123330) has net assets worth ₩55.79 Billion KRW (≈ $37.81 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩90.92 Billion ≈ $61.61 Million USD) and total liabilities (₩35.13 Billion ≈ $23.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Genic Co. Ltd to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩55.79 Billion |
| % of Total Assets | 61.36% |
| Annual Growth Rate | -1.93% |
| 5-Year Change | 112.71% |
| 10-Year Change | -33.72% |
| Growth Volatility | 38.35 |
Genic Co. Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Genic Co. Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Genic Co. Ltd.
Annual Net Assets for Genic Co. Ltd (2012–2025)
The table below shows the annual net assets of Genic Co. Ltd from 2012 to 2025. Also explore Genic Co. Ltd net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩41.05 Billion ≈ $27.82 Million |
+85.28% |
| 2024-12-31 | ₩22.15 Billion ≈ $15.01 Million |
+92.12% |
| 2023-12-31 | ₩11.53 Billion ≈ $7.81 Million |
-27.67% |
| 2022-12-31 | ₩15.94 Billion ≈ $10.80 Million |
-17.38% |
| 2021-12-31 | ₩19.30 Billion ≈ $13.08 Million |
-13.59% |
| 2020-12-31 | ₩22.33 Billion ≈ $15.13 Million |
-17.72% |
| 2019-12-31 | ₩27.14 Billion ≈ $18.39 Million |
-30.31% |
| 2018-12-31 | ₩38.94 Billion ≈ $26.39 Million |
-28.25% |
| 2017-12-31 | ₩54.27 Billion ≈ $36.78 Million |
-12.37% |
| 2016-12-31 | ₩61.93 Billion ≈ $41.97 Million |
+6.70% |
| 2015-12-31 | ₩58.04 Billion ≈ $39.33 Million |
+5.23% |
| 2014-12-31 | ₩55.16 Billion ≈ $37.38 Million |
+3.59% |
| 2013-12-31 | ₩53.25 Billion ≈ $36.08 Million |
+0.72% |
| 2012-12-31 | ₩52.87 Billion ≈ $35.83 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genic Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1271219352000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩12.71 Billion | 30.97% |
| Other Components | ₩28.34 Billion | 69.03% |
| Total Equity | ₩41.05 Billion | 100.00% |
Genic Co. Ltd Competitors by Market Cap
The table below lists competitors of Genic Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Biosyent Inc.
V:RX
|
$130.19 Million |
|
Sigachi Industries Limited
NSE:SIGACHI
|
$130.21 Million |
|
Smith-Midland Corp
NASDAQ:SMID
|
$130.22 Million |
|
Endeavour Mining Corp
LSE:EDV
|
$130.24 Million |
|
Digital Multimedia Technology Co.Ltd
KQ:134580
|
$130.14 Million |
|
Siam Pan Group PCL
BK:SPG
|
$130.12 Million |
|
DongWon Development Co.Ltd
KQ:013120
|
$130.04 Million |
|
Shriram Properties Limited
NSE:SHRIRAMPPS
|
$129.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genic Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 22,154,400,820 to 41,047,610,230, a change of 18,893,209,410 (85.3%).
- Net income of 18,886,570,770 contributed positively to equity growth.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩18.89 Billion | +46.01% |
| Other Changes | ₩6.64 Million | +0.02% |
| Total Change | ₩- | 85.28% |
Book Value vs Market Value Analysis
This analysis compares Genic Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.68x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.72x to 4.68x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩9025.19 | ₩24550.00 | x |
| 2017-12-31 | ₩7913.09 | ₩24550.00 | x |
| 2018-12-31 | ₩5679.82 | ₩24550.00 | x |
| 2019-12-31 | ₩3958.51 | ₩24550.00 | x |
| 2020-12-31 | ₩3257.13 | ₩24550.00 | x |
| 2021-12-31 | ₩2814.64 | ₩24550.00 | x |
| 2022-12-31 | ₩2325.39 | ₩24550.00 | x |
| 2023-12-31 | ₩1681.95 | ₩24550.00 | x |
| 2024-12-31 | ₩2831.35 | ₩24550.00 | x |
| 2025-12-31 | ₩5245.91 | ₩24550.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genic Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 46.01%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.15%
- • Asset Turnover: 1.38x
- • Equity Multiplier: 1.38x
- Recent ROE (46.01%) is above the historical average (-6.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 10.74% | 6.62% | 1.43x | 1.14x | ₩392.57 Million |
| 2013 | 6.48% | 5.55% | 0.96x | 1.22x | ₩-1.87 Billion |
| 2014 | 3.55% | 3.08% | 0.84x | 1.37x | ₩-3.56 Billion |
| 2015 | 5.04% | 3.97% | 0.85x | 1.50x | ₩-2.88 Billion |
| 2016 | 1.98% | 1.37% | 0.88x | 1.64x | ₩-4.97 Billion |
| 2017 | -13.76% | -11.54% | 0.69x | 1.72x | ₩-12.89 Billion |
| 2018 | -39.35% | -22.20% | 0.94x | 1.88x | ₩-19.22 Billion |
| 2019 | -44.07% | -22.88% | 0.90x | 2.14x | ₩-14.67 Billion |
| 2020 | -19.50% | -10.33% | 0.84x | 2.24x | ₩-6.59 Billion |
| 2021 | -22.44% | -11.28% | 0.85x | 2.35x | ₩-6.26 Billion |
| 2022 | -20.95% | -10.62% | 1.04x | 1.90x | ₩-4.93 Billion |
| 2023 | -38.25% | -15.71% | 1.20x | 2.03x | ₩-5.56 Billion |
| 2024 | 34.14% | 15.15% | 1.31x | 1.72x | ₩5.35 Billion |
| 2025 | 46.01% | 24.15% | 1.38x | 1.38x | ₩14.78 Billion |
Industry Comparison
This section compares Genic Co. Ltd's net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $770,650,472,039
- Average return on equity (ROE) among peers: 4.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genic Co. Ltd (123330) | ₩55.79 Billion | 10.74% | 0.63x | $130.18 Million |
| Amore Group (002790) | $1.02 Trillion | 15.50% | 0.44x | $1.36 Billion |
| Amorepacific Group (002795) | $5.93 Trillion | 3.42% | 0.24x | $100.90 Million |
| Hankook Cosmetics Manufacturing Co Ltd (003350) | $44.27 Billion | -9.08% | 0.75x | $181.91 Million |
| Daelim Trading (006570) | $142.74 Billion | 4.65% | 1.37x | $20.13 Million |
| Monalisa (012690) | $68.62 Billion | 7.93% | 0.17x | $36.17 Million |
| Medience Co. LTD (014100) | $49.90 Billion | 6.37% | 1.40x | $12.94 Million |
| Leaders Cosmetics Co. Ltd (016100) | $81.01 Billion | -7.27% | 1.38x | $15.79 Million |
| Aekyung Industrial Co Ltd (018250) | $309.11 Billion | 19.67% | 0.33x | $194.29 Million |
| Kolmar Holding (024720) | $48.25 Billion | 5.20% | 0.61x | $219.17 Million |
| Jayjun Co Ltd (025620) | $7.80 Billion | 0.00% | 6.30x | $57.83 Million |
About Genic Co. Ltd
Genic Co., Ltd. researches, develops, manufactures, and sells cosmetics and pharmaceuticals in South Korea and internationally. The company provides hydrogel masks, sheet masks, cream wrapping masks, mud masks, and bio cellulose masks; nose patch, eye patch, body patch, eye gel, lifting patch, and outdoor patches; cleanser, toner, lotion, serum, cream, sunscreen, and cleansing/soothing/oil pad; a… Read more